Vaccines protective against gram-negative bacteremia and endotoxic shock and related diagnosic assays
CA 2071069 A1 · Owner: The Research Foundation Of State University Of New York · Inventors: Ward, Ronald E.; Mcnamara-Ward, Mary; Apicella, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to the development of monoclonal anti-idiotypic antibodies (anti-ids) which mimic a common antigenic determinant on the lipid A portion of the Lipopolysaccharite (LPS) of gram-negative bacteria. More particularly, the invention comprises the development of hybridomas A4, H9, and H12 which produce monoclonal anti-Ids that mimic a common antigenic determinant on the lipid A portion of the LPS molecule found on a number of different bacterial strains. The development of the hybridomas was carried out by induction with a monoclonal antibody, 1C9 which recognizes a, conserved epitope, that is a target for a bactericidal antibody or involved in immune clearance …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 11, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 11, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 11, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.